We are led by a team of industry veterans who have a successful track record of taking molecules from bench to bedside and who have a passion to make a meaningful difference in the lives of patients and their families.
Jill C. Milne, Ph.D.
Co-Founder and Chief Executive Officer
Jill C. Milne, Ph.D., is a co-founder of our company and has served as a member of our board of directors and as our President and Chief Executive Officer since June 2008.
READ MORE Prior to co-founding our company, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. From 1998 to 2004, Dr. Milne worked at Pfizer Global Research and Development, where she served as the worldwide head of the Drug Pfinder Program and head of the Enzyme Target Group at the Pfizer Discovery Technology Center in Cambridge, Massachusetts. Prior to joining Pfizer, she was an American Cancer Society postdoctoral fellow in the department of biological chemistry and molecular pharmacology at Harvard Medical School from 1995 to 1998. Dr. Milne holds a Ph.D. from Harvard University and a B.A. in biological chemistry from Wellesley College.
Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer and Senior Vice President, Clinical Development
Joanne Donovan, M.D., Ph.D., has served as our Chief Medical Officer since July 2011.
READ MORE In this role, Joanne also has responsibilities for global regulatory affairs. In addition, since 1989, she worked as a staff physician at the VA Boston Healthcare System, where she was formerly Chief of Gastroenterology. Dr. Donovan has held an appointment at Harvard Medical School since 1990, most recently as associate clinical professor of medicine. From 1998 to July 2011, Dr. Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme Corporation, a publicly traded biotechnology company, which she joined through its acquisition of GelTex. Dr. Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the Brigham and Women’s Hospital.
Chief Business Officer
Ted Hibben joined Catabasis in April 2015 and currently serves as Chief Business Officer.
READ MORE He brings to Catabasis over 20 years of biotech experience in business and corporate development, strategy, fundraising and M&A, specializing in product platform drug discovery and development companies. Ted came to Catabasis from Ensemble Therapeutics where, as head of corporate and business development, he formed four multi-year multi-target discovery and development-stage collaborations with pharmaceutical companies eligible for over $1 billion in future success milestone payments for programs emerging from Ensemble’s macrocycle library platforms. Prior to Ensemble, Ted was Chief Business Officer at the RNAi product platform company, Cequent Pharmaceuticals, where he played an instrumental role in its merger with MDRNA, Inc. (now Marina Biotech), and was Vice President, Business Development and Alliance Management, at immunomodulatory company, Coley Pharmaceutical Group, where he sourced and/or managed nine development alliances and led the process to sell Coley to Pfizer. Ted earned his M.B.A. from Harvard University and his A.B. from Dartmouth College.
Andrew Nichols, Ph.D.
Chief Scientific Officer
Andrew Nichols joined Catabasis in 2014 and currently serves as Chief Scientific Officer.
READ MORE Dr. Nichols brings to Catabasis 25 years of drug development experience, leading efforts from target discovery through translational research and early clinical development for pharmaceutical and biotechnology companies. Prior to joining Catabasis, Dr. Nichols was Associate Vice President, Cardiometabolic Diseases at Merck Research Labs, leading drug discovery and early clinical development programs. Prior to Merck, Dr. Nichols was Vice President of Preclinical Research at Zafgen, Vice President of Research at Alinea, Vice President of Drug Discovery Project Leadership at Millennium and Director of the Alliance Management Group at SmithKline Beecham. He has worked across multiple therapeutic areas (cardiovascular, metabolic, oncology and inflammation), utilizing a combination of internal and external sourcing strategies. He holds his B.Sc. in Pharmacology from the University of Leeds, England, and his M. Phil. and Ph.D. in Cardiovascular Pharmacology from the University of Cambridge, England.
Senior Vice President, General Counsel
Deirdre A. Cunnane, J.D., joined Catabasis in November 2015 as Senior Vice President, General Counsel.
READ MORE She brings to Catabasis over 25 years of legal counsel experience. Ms. Cunnane came to Catabasis from Advanced Technology Ventures (ATV), a venture capital firm, where she served as General Counsel from January 2006 to October 2015. She also served as General Counsel of Lightstone Ventures, a venture capital firm, from its founding in January 2012 until October 2015. As General Counsel of ATV and Lightstone, Ms. Cunnane provided legal counsel in connection with structuring investment securities and complex capital restructurings from seed to later stage investments, as well as mergers and acquisitions and general corporate governance. Prior to ATV and Lightstone, Ms. Cunnane was an investment officer at BancBoston Ventures and Deputy General Counsel at BancBoston Capital. Ms. Cunnane started her law career with, and later became a Partner in, Goodwin Procter, LLP's Corporate Department. Ms. Cunnane holds a J.D. from Boston College Law School and a B.S. in Finance from the Boston College School of Management.
Angelika Fretzen, Ph.D.
Senior Vice President, Product Development
Angelika Fretzen joined Catabasis in 2014. Prior to joining Catabasis she was Vice President of Pharmaceutical Chemistry and Development at Ironwood Pharmaceuticals.
READ MORE Dr. Fretzen led Pharmaceutical Development and CMC related aspects of Ironwood's linaclotide program through the approval as Linzess® in the US and as ConstellaTM in Canada and Europe. She has been responsible for discovery and development programs for small molecules and peptides in a variety of different disease areas. Prior to joining Ironwood Pharmaceuticals, Dr. Fretzen was an Alexander von Humboldt Fellow in the Department of Chemistry and Chemical Biology at Harvard University. She holds a Diploma (M.S.) in chemistry from the University of Würzburg in Germany and her Ph.D. in organometallic and synthetic organic chemistry from the University of Geneva, Switzerland. In addition Dr. Fretzen has received an MBA from Suffolk University in Boston.
Vice President, Regulatory Affairs
Joseph Johnston joined Catabasis in 2016 as Vice President of Regulatory Affairs.
READ MORE Prior to joining Catabasis, Mr. Johnston was at Ionis Pharmaceuticals (formerly Isis Pharmaceuticals), a biopharmaceutical company in RNA-targeted drug discovery and development, where he served as Vice President, Regulatory Affairs and Quality from 2008 to May 2016. Previously, Mr. Johnston held a series of roles with increasing responsibilities at Isis Pharmaceuticals from 1990, when he was part of the original scientific team, to 2008. In his time at Ionis Pharmaceuticals, Mr. Johnston provided global regulatory leadership on hundreds of regulatory applications including experience with rare diseases as well as pediatric indications. Mr. Johnston holds a M.B.A. from University of California Irvine and a M.S. in Pharmacology and a B.A. in Biology, both from the University of Pennsylvania.